RT Journal Article SR Electronic T1 The 24-h FEV1 time profile of olodaterol QD delivered via Respimat® in COPD: Results from two 6-week studies JF European Respiratory Journal JO Eur Respir J FD European Respiratory Society SP 4635 VO 42 IS Suppl 57 A1 Peter Lange A1 Joseph-Leon Aumann A1 Eric Derom A1 Alan Hamilton A1 Kay Tetzlaff A1 Naitee Ting A1 Jan Arie van Noord YR 2013 UL http://erj.ersjournals.com/content/42/Suppl_57/4635.abstract AB Background: Olodaterol (O) is a novel inhaled LABA.Objective: To evaluate the 24-h lung function profile of O QD in patients (pts) with GOLD 2-4 COPD.Methods: In two replicate, randomised, double-blind, placebo (P)-controlled, 6-week (wk), crossover studies, pts received O (5 or 10 µg) QD via Respimat®, tiotropium (T; 18 µg) QD via HandiHaler® or P for 6 wks (Study 1: NCT01040689; Study 2: NCT01040728). Pts continued with ICS and xanthines as background therapy. Co-primary end points were change from study baseline (response) in FEV1 AUC0-12 and FEV1 AUC12-24; secondary end points were FEV1 AUC0-3, FEV1 AUC0-24 and trough FEV1 response after 6 wks of treatment.Results: 108 and 122 pts were treated in Studies 1 and 2, respectively. Significant bronchodilation vs P was evident over the full 24-h dosing interval for O and T QD.Statistically significant (p<0.001) improvements were observed in all lung function end points with O 5 and 10 µg and T vs P.View this table:Conclusions: These data confirm the 24-h lung function efficacy profile of O QD.Funding: Boehringer Ingelheim.